ArticleNeuroImage2021
Robust parametric modeling of Alzheimer's disease progression.
Article in NeuroImage, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- LNODE: Uncovering the Latent Dynamics ofMedical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2026Article
- Laplacian Eigenfunction-Based Neural Operator for Learning Nonlinear Reaction-Diffusion Dynamics.Journal of computational physics · 2025Article
- Aligning personalized biomarker trajectories onto a common time axis: a connectome-based ODE model for Tau-Amyloid beta dynamics.Medical image analysis · 2025Article
- Cross-Dataset Evaluation of Dementia Longitudinal Progression Prediction Models.Human brain mapping · 2025Article
- Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Detection of Alzheimer's disease using Otsu thresholding with tunicate swarm algorithm and deep belief network.Frontiers in physiology · 2024Article
- Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts.Frontiers in aging neuroscience · 2024Article
- Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients.Current Alzheimer research · 2024Article
- Detection of Alzheimer's disease onset using MRI and PET neuroimaging: longitudinal data analysis and machine learning.Neural regeneration research · 2023Review
- An ontology-based approach for harmonization and cross-cohort query of Alzheimer's disease data resources.BMC medical informatics and decision making · 2023Article
- Vascular endothelial-cadherin as a marker of endothelial injury in preclinical Alzheimer disease.Annals of clinical and translational neurology · 2022Article
- Deep Learning Model for Prediction of Progressive Mild Cognitive Impairment to Alzheimer's Disease Using Structural MRI.Frontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Quantitative characterization of disease progression using longitudinal data can provide long-term predictions for the pathological stages of individuals. This work studies the robust modeling of Alzheimer's disease progression using parametric methods. The proposed method linearly maps the individual's age to a disease progression score (DPS) and jointly fits constrained generalized logistic functions to the longitudinal dynamics of biomarkers as functions of the DPS using M-estimation. Robustness of the estimates is quantified using bootstrapping via Monte Carlo resampling, and the estimated inflection points of the fitted functions are used to temporally order the modeled biomarkers in the disease course. Kernel density estimation is applied to the obtained DPSs for clinical status classification using a Bayesian classifier. Different M-estimators and logistic functions, including a novel type proposed in this study, called modified Stannard, are evaluated on the data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) for robust modeling of volumetric magnetic resonance imaging (MRI) and positron emission tomography (PET) biomarkers, cerebrospinal fluid (CSF) measurements, as well as cognitive tests. The results show that the modified Stannard function fitted using the logistic loss achieves the best modeling performance with an average normalized mean absolute error (NMAE) of 0.991 across all biomarkers and bootstraps. Applied to the ADNI test set, this model achieves a multiclass area under the ROC curve (AUC) of 0.934 in clinical status classification. The obtained results for the proposed model outperform almost all state-of-the-art results in predicting biomarker values and classifying clinical status. Finally, the experiments show that the proposed model, trained using abundant ADNI data, generalizes well to data from the National Alzheimer's Coordinating Center (NACC) with an average NMAE of 1.182 and a multiclass AUC of 0.929.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.